Genmab A/S (GMAB)

Genmab develops antibody-based medicines for the treatment of cancer and other serious diseases using its proprietary bispecific and other antibody technology platforms. It creates differentiated therapeutics that it advances through its own research programs and collaborations with larger pharmaceutical partners. Approved products originating from its platforms are commercialized by partners while the company progresses additional candidates in clinical development.

Market

Copenhagen

Sector

Healthcare

Trend

Strong uptrend

Last close

2,165 (-1.46% on the day)

MA50

1,969.64

MA200

1,883.49

52-week range

1,524–2,251

Market cap

134.4B DKK

P/E

26.6

Dividend yield

0%

Data as of

2026-09-04

All markets — KeepWinning global stock screener

Other companies on Copenhagen: Coloplast A/S (COLO B), Tryg A/S (TRYG), Pandora A/S (PNDORA), Jyske Bank A/S (JYSK), Demant A/S (DEMANT), AL Sydbank A/S (ALSYDB)